source
- FDA, AstraZeneca prep for oncology adcommThe FDA is set to convene its first advisory meeting of oncology experts in about nine months, with a couple of AstraZeneca drugs as the focus of the discussion. Details about the meeting of the ...Endpoints · 3mo ago↗ source
- Teva nabs experimental Tourette drug in $700M Emalex buyoutA Jefferies analyst argued the deal — Teva’s largest in a decade — “makes sense” given the synergies between Emalex and the pharmaceutical giant’s neurology business.BioPharma Dive · 3mo ago↗ source
- Chiesi to buy KalVista in $1.9B deal for rare disease drugThe acquisition is the fifth of a biotech company so far this week and, according to some Wall Street analysts, proves pharma’s interest in new and emerging oral therapies for hereditary angioedema.BioPharma Dive